In this article LLY BMY MRK PFE UTHR RDW XBI Follow your favorite stocksCREATE FREE ACCOUNT The highly anticipated SpaceX mega-IPO is part of a
Read more
Author: DG
Is Frozen Yogurt Better for You Than Ice Cream?
[unable to retrieve full-text content] We asked experts whether its health reputation is deserved.
Read moreAlcohol’s Health Risks Accelerate After One Drink a Day, Study Finds
[unable to retrieve full-text content] The alcohol industry has criticized the research, which found that even light drinking increases the risk of premature death.
Read more
Apple shares slide after big Siri AI reveal
In this article AAPL Follow your favorite stocksCREATE FREE ACCOUNT Apple shares fell 3% on Tuesday, a day after the company revealed new artificial intelligence
Read more
JPMorgan Chase plans to deploy more powerful AI agents this year
In this article JPM Follow your favorite stocksCREATE FREE ACCOUNT A person exits the JPMorgan Chase & Co. headquarters on Feb. 17, 2026, in New
Read more
SpaceX employee group creates low-fee wealth management option with Choreo for post-IPO
In this article SPCX Follow your favorite stocksCREATE FREE ACCOUNT SpaceX signage outside the Space Exploration Technologies Corp. facility in Hawthorne, California, on June 3,
Read more
The Laser That Once Filled a Lab Now Fits on a Tiny Chip
Placed on a 1 CHF coin for scale, EPFL’s photonic chip shows how a laser architecture once confined to table-top systems can be shrunk to
Read more
The Next Computing Revolution May Come From Stacking Chips Like Skyscrapers
Scientists have demonstrated a breakthrough method for building true 3D silicon chips by stacking multiple layers of circuits without damaging existing electronics. The advance could
Read more
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
GlaxoSmithKline headquarters in London on Jan. 17, 2022. Hannah Mckay | Reuters UK pharmaceutical group GSK is in talks to acquire oncology biotech Nuvalent for
Read more
Jim Cramer says he can’t sell Eli Lilly despite its massive run up. Here’s why
Eli Lilly ‘s expanding obesity drug pipeline is giving us little reason to take profits at this point — even after a massive run to
Read more